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Background-—Conﬂicting data exist about the cardiovascular risk of metabolically healthy obese persons. The prognostic value of
C-reactive protein (CRP) in this intriguing group is unknown. We assessed the association between CRP levels and the risk of
coronary heart disease (CHD) in metabolically healthy persons with abdominal obesity.
Methods and Results-—In the European Prospective Investigation of Cancer–Norfolk prospective cohort, CRP levels and
information on metabolic syndrome criteria were available for 7279 participants, of whom 825 (11%) developed CHD during a
follow-up period of 10.91.8 years. There was a trend toward a higher multivariable-adjusted hazard ratio for CHD in metabolically
healthy obese participants with CRP levels >2 mg/L compared with <2 mg/L (hazard ratio 1.59, 95% CI 0.97–2.62, P=0.066).
Metabolically unhealthy obese participants had signiﬁcantly higher CHD risk compared with metabolically healthy obese
participants with CRP levels <2 mg/L (hazard ratio 1.88, 95% CI 1.20–2.94, P=0.006). Most important, we found that the risk of
CHD among metabolically healthy obese persons with CRP levels <2 mg/L was comparable to that of metabolically healthy
nonobese persons (hazard ratio 0.91, 95% CI 0.60–1.39, P=0.674).
Conclusions-—Among metabolically healthy obese persons, low CRP levels were associated with a CHD risk comparable to that of
metabolically healthy nonobese persons. CRP appears to be an easy and widely available method for identifying a low-risk
subpopulation among metabolically healthy obese persons. ( J Am Heart Assoc. 2016;5:e002823 doi: 10.1161/
JAHA.115.002823)
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C -reactive protein (CRP) is an acute-phase protein of thefamily of the pentraxins and is widely used in clinical
settings to monitor chronic and acute inﬂammatory condi-
tions.1 The positive association between CRP levels and the
risk of future coronary heart disease (CHD) has been studied
extensively.2,3 The metabolic syndrome (MS) represents a
cluster of risk factors for cardiovascular disease and type 2
diabetes mellitus, which coexist more often than by chance
alone. It is widely accepted that the spectrum of MS includes
abdominal obesity, hypertension, hypertriglyceridemia, low
high-density lipoprotein cholesterol (HDL-C), and glucose
intolerance, although the exact cutoff values are debated.4,5
Two large meta-analyses have shown that the presence of MS
raises CHD risk 2-fold.6,7 Experimental and observational
evidence suggests that inﬂammation may play a central role
in the pathogenesis of cardiovascular disease.8 CRP is
associated with all parameters of the MS9 and has been
acknowledged to be an independent but not causal2,10 risk
factor for incident CHD and to add prognostic value for CHD
risk on top of the MS criteria.3,9,11–14
The presence of obesity-related metabolic disturbances
varies widely among obese persons. Metabolically healthy
obese persons are characterized by having excessive body fat
while displaying a favorable metabolic proﬁle characterized by
high levels of insulin sensitivity; no hypertension; and a
favorable lipid, inﬂammation, hormonal, liver enzyme, and
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immune proﬁle.15 Recent studies have indicated that this
healthier metabolic proﬁle may not translate into a lower risk
for mortality,16,17 whereas other studies suggested that this
population might have cardiovascular risk comparable to
metabolically healthy nonobese persons.18,19 To the best of
our knowledge, the role of CRP in the assessment of CHD risk
has not been described previously in metabolically healthy
obese persons. We set out to determine the associations
between CRP levels and the risk of CHD in this group. We
tested the following hypotheses: Metabolically healthy obese
persons with low levels of CRP (1) have lower cardiovascular
risk than metabolically unhealthy obese persons with elevated
levels of CRP and (2) have comparable risk of cardiovascular
events compared with metabolically healthy nonobese per-
sons. We examined these hypotheses in the European




EPIC-Norfolk is a prospective population study of 25 639
male and female inhabitants of Norfolk, United Kingdom, aged
39 to 79 years. Brieﬂy, EPIC-Norfolk is part of the 10-country
collaborative EPIC study designed to investigate determinants
of cancer. Additional data were obtained to enable assess-
ment of determinants of other diseases such as CHD. At the
baseline survey between 1993 and 1997, participants com-
pleted a detailed health and lifestyle questionnaire with
additional data collection performed by trained nurses at a
clinic visit. The study cohort was similar to UK population
samples with regard to many characteristics including
anthropometry, blood pressure, and lipids but with a lower
proportion of smokers. Full details of the population were
reported elsewhere.20
MS criteria were deﬁned as described previously, with
minor modiﬁcations.4 Abdominal obesity, obese persons, and
obesity were all deﬁned as an elevated waist circumference
≥102 cm (≥40 in) in men and ≥89 cm (≥35 in) in women.
Hypertension was deﬁned as systolic blood pressure
≥130 mm Hg, diastolic blood pressure ≥85 mm Hg, or use
of antihypertensive medication.2 Hypertriglyceridemia was
deﬁned as triglyceride levels ≥150 mg/dL (1.7 mmol/L),
whereas low HDL-C was deﬁned as HDL-C <40 mg/dL
(1.03 mmol/L) in men or HDL-C <50 mg/dL (1.30 mmol/L)
in women. Hyperglycemia was deﬁned as glycated hemoglo-
bin HbA1c ≥6% or being on antidiabetic medication at
inclusion. Participants were considered metabolically healthy
when no or 1 MS criterion was present. Metabolically
unhealthy was deﬁned as the presence of ≥2 MS criteria.
Metabolically healthy abdominally obese persons were
deﬁned as having an elevated waist circumference ≥102 cm
(≥40 in) in men and ≥89 cm (≥35 in) in women without the
presence of any of the other MS criteria.
All participants were ﬂagged for mortality at the UK Ofﬁce
of National Statistics, with vital status ascertained for the
entire cohort. The death certiﬁcates were coded by trained
nosologists according to the International Classiﬁcation of
Diseases, 10th revision (ICD-10). In addition, participants were
identiﬁed using their unique National Health Service numbers
through data linkage with the East Norfolk Health Authority
(ENCORE) database, which identiﬁes all hospital contacts
throughout England and Wales for residents of Norfolk.
Participants were identiﬁed as having a CHD event if the
corresponding ICD-10 code (I20–I25) was recorded as the
underlying cause of that hospitalization or mortality. The study
complied with the Declaration of Helsinki. The Norwich
District Health Authority ethics committee approved the
study, and all participants gave signed informed consent.
Laboratory Measurements
Nonfasting blood samples were drawn into plain and citrate
bottles. Blood samples were processed directly at the
Department of Clinical Biochemistry, University of Cambridge,
or stored at 80°C. Serum levels of total cholesterol, HDL-C,
and triglycerides were measured in fresh samples with RA
1000 (Bayer Diagnostics). Low-density lipoprotein cholesterol
levels were calculated using the Friedewald formula. Because
of limited funding, HbA1c levels were measured for partici-
pants from 1995 only; this approximates a random subset of
the cohort. HbA1c was measured on fresh EDTA blood
samples using high-performance liquid chromatography (Dia-
mat Automated Glycated Hemoglobin Analyzer; Bio-Rad
Laboratories Ltd). When additional funding became available
in 2010, serum concentrations of CRP were measured for all
participants with available frozen baseline serum samples
using a full-range, high-sensitivity assay on an Olympus
AU640 clinical chemistry analyzer (Olympus UK Ltd).
Statistical Analysis
For the current analysis, study participants with missing data
for CRP, waist circumference, lipids, blood pressure, HbA1c,
or use of antihypertensive or antidiabetic medication were
excluded. Summary data are presented as meanSD for
continuous variables with a normal distribution, as median
and interquartile range (IQR) for continuous variables with a
non-normal distribution, and as percentage (number) for
categorical variables. Because triglycerides and CRP were not
normally distributed, these parameters were log-transformed
before analysis. A 2-sided t test was used to test differences
between groups for continuous variables, and a chi-square
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test was used for categorical variables. A Cox proportional
hazards model was used to assess the association between
CRP levels and CHD. Associations were expressed as hazard
ratios (HRs) and corresponding 95% CIs per 1-SD increment in
(log-transformed) CRP. Participants were censored at the time
of the ﬁrst occurrence of the cardiovascular event analyzed,
the time of death, or the end of follow-up, which was March
31, 2008, whichever came ﬁrst. Three Cox regression models
were performed to investigate the relation of CHD event rates,
CRP, and (1) metabolically healthy or unhealthy persons, (2)
persons with or without abdominal obesity, or (3) metabol-
ically healthy or unhealthy persons with or without abdominal
obesity. All models were adjusted for sex and age or for sex,
age, smoking status, the use of lipid-lowering medication at
baseline, and low-density lipoprotein cholesterol. Subgroup
analyses to test for a possible interaction between sex and
CRP was performed by the inclusion of an interaction term in
the multivariable corrected model. The proportional hazards
assumption was met for each variable in the model applied.
The predeﬁned level of signiﬁcance was set at 0.05. Analyses
were performed using IBM SPSS statistics version 20 (IBM
Corp).
Results
CRP Levels and the MS Criteria
A complete data set on CRP levels, abdominal obesity,
hypertension, hypertriglyceridemia, HDL-C, and HbA1c was
available for 7279 participants. Table 1 shows the baseline
characteristics according to metabolic phenotype and CRP
level for the study participants. The mean age was 58 years,
and 57% of participants were women. During follow-up, 825
(11%) CHD events occurred. There was a positive association
between CRP level and number of MS criteria. CRP levels for
those with 0, 1, 2, 3, or ≥4 MS criteria were 0.8 mg/L (IQR
0.4–1.7 mg/L), 1.2 mg/L (IQR 0.6–2.4 mg/L), 1.5 mg/L
(IQR 0.8–3.1 mg/L), 2.2 mg/L (IQR 1.2–4.3 mg/L), and




P Value† P Value‡ AllCRP <2 mg/L CRP ≥2 mg/L CRP <2 mg/L CRP ≥2 mg/L
Participants, n (%) 2685 (37) 997 (14) — 1791 (25) 1806 (25) — — 7279
Age, y 55.79.2 58.39.0 — 59.59.3 62.28.8 — — 58.49.4
Women, n (%) 1872 (64) 842 (67) <0.001 647 (42) 790 (51.3) <0.001 <0.001 4151 (57)
Body mass index, kg/m2 24.63.0 26.53.9 <0.001 26.73.3 28.64.4 <0.001 <0.001 26.23.9
Waist circumference, cm 82.610.9 87.011.6 <0.001 91.311.0 95.611.6 <0.001 <0.001 88.012.4
Current smoker, n (%) 293 (10) 175 (14) <0.001 132 (9) 234 (15) <0.001 0.333 834 (11)
Diabetes mellitus, n (%) 10 (0.3) 8 (0.6) 0.182 55 (3.6) 76 (4.9) 0.061 <0.001 149 (2.0)
Myocardial infarction at baseline, n (%) 29 (1.0) 22 (1.7) 0.040 68 (4.4) 104 (6.7) <0.001 <0.001 223 (3.1)
Systolic blood pressure, mm Hg 12816 13218 <0.001 14017 14317 <0.001 <0.001 13418
Diastolic blood pressure, mm Hg 7910 8111 <0.001 8611 8610 0.405 <0.001 8211
Total cholesterol, mmol/L 5.881.01 5.991.05 0.002 6.321.15 6.391.18 0.138 <0.001 6.10 1.11
LDL-C, mmol/L 3.720.94 3.800.98 0.012 4.081.03 4.121.04 0.208 <0.001 3.901.00
HDL-C, mmol/L 1.630.40 1.610.40 0.141 1.230.35 1.210.34 0.086 <0.001 1.450.43
Triglycerides, mmol/L 1.1 (0.9–1.5) 1.2 (1.0–1.5) <0.001 2.2 (1.8–2.7) 2.2 (1.8–2.8) 0.017 <0.001 1.5 (1.1–2.2)
HbA1c, % 5.090.51 5.180.55 <0.001 5.460.91 5.761.15 <0.001 <0.001 5.30.83
CRP, mg/L 0.7 (0.4–1.2) 3.6 (2.5–6.1) <0.001 1.0 (0.6–1.4) 4.0 (2.8–6.6) <0.001 <0.001 1.4 (0.7–3.0)
Use of lipid-lowering drugs at baseline,
n (%)
5 (0) 3 (0) 0.646 55 (3.6) 64 (4.2) 0.402 <0.001 127 (2)
Hormone replacement therapy, n (%) 344 (11.7) 298 (23.6) <0.001 78 (5.1) 181 (11.7) <0.001 <0.001 904 (12.4)
Data are presented as meanSD or number (percentage). Triglyceride and CRP are presented as median with the 25th to 75th percentiles. CRP indicates C-reactive protein; HbA1c,
glycated hemoglobin A1c; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol.
*P value of comparison within metabolically healthy groups with different levels of CRP.
†P value of comparison within metabolically unhealthy groups with different levels of CRP.
‡P value for comparison between metabolically healthy and unhealthy groups independent of CRP level.
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3.0 mg/L (IQR 1.6–5.7 mg/L), respectively (P for trend
<0.001). Likewise, CRP levels were signiﬁcantly higher in
participants with versus without abdominal obesity indepen-
dent of MS criteria (P for trend <0.001). Figure 1 displays the
median and the 25th and 75th percentiles of the CRP
distribution according to the number of MS criteria and the
presence of abdominal obesity.
CRP and CHD Risk in Metabolically Healthy and
Unhealthy Persons
HRs for CHD according to the presence or absence of
metabolic health, abdominal obesity, and CRP level are shown
in Table 2. Among metabolically unhealthy participants, those
with CRP ≥2 mg/L had signiﬁcantly higher CHD risk than
those with CRP <2 mg/L (HR 1.37, 95% CI 1.16–1.63,
P<0.001). Metabolically healthy participants with CRP levels
<2 mg/L had a signiﬁcantly lower risk than metabolically
unhealthy participants with CRP levels <2 mg/L (HR 0.53,
95% CI 0.43–0.65, P<0.001). Compared with sex- and age-
adjusted HRs, additional adjustment for smoking status, the
use of lipid-lowering medication at baseline, and low-density
lipoprotein cholesterol did not change these results impor-
tantly (HR 1.31, 95% CI 1.10–1.56, P=0.002, and HR 0.60,
95% CI 0.48–0.73, P<0.001, respectively).
CRP and CHD in Obese and Nonobese Persons
Among participants with abdominal obesity, those with CRP
≥2 mg/L had signiﬁcantly higher CHD risk compared with
those with a CRP level <2 mg/L (HR 1.45, 95% CI 1.14–1.85,
P=0.002). Nonobese participants with CRP levels <2 mg/L
had a signiﬁcantly lower risk than those with abdominal
obesity and CRP levels <2 mg/L (HR 0.73, 95% CI 0.58–0.92,
P=0.008). Compared with sex- and age-adjusted HRs, addi-
tional adjustment for smoking status, lipid-lowering medica-
tion at baseline, and low-density lipoprotein cholesterol did
not change the results importantly (HR 1.38, 95% CI 1.08–
1.75, P=0.010, and HR 0.75, 95% CI 0.59–0.94; P=0.013,
respectively).
CRP and CHD in Metabolically Healthy and
Unhealthy Obese Persons
The risk of CHD for metabolically unhealthy obese partici-
pants with CRP <2 mg/L was signiﬁcantly higher compared
with metabolically healthy obese participants with CRP
<2 mg/L (HR 1.88, 95% CI 1.20–2.94, P=0.006). The risk
of CHD for metabolically healthy obese participants with
CRP ≥2 mg/L was higher than that for metabolically healthy
participants with CRP <2 mg/L (HR 1.59, 95% CI 0.97–2.62,
P=0.066), although this trend did not reach statistical
signiﬁcance. Importantly, metabolically healthy participants
without abdominal obesity had CHD risk comparable to
metabolically healthy obese participants with CRP levels
<2 mg/L (HR 0.91, 95% CI 0.60–1.39, P=0.674, for CRP
<2 mg/L; HR 1.22, 0.78–1.91, P=0.387, for CRP >2 mg/L).
Because sex is known to inﬂuence both CRP levels and CHD
risk, we performed a subgroup analysis by sex to investigate
a possible interaction between sex and CRP levels for risk of
CHD. We did not ﬁnd a statistical difference for the
interaction of sex and CRP in the multivariable adjusted
Figure 1. Distribution of CRP levels according to the number of MS criteria and the presence of
abdominal obesity. Plots display the median and 25th and 75th percentiles of the CRP distribution. A
Kruskal–Wallis nonparametric test demonstrated P<0.01 between number of MS criteria groups. A Mann–
Whitney U test was used to test for signiﬁcant differences in CRP level within the number of MS criteria
groups. ***P<0.01. CRP indicates C-reactive protein; MS, metabolic syndrome; ns, not signiﬁcant.
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model (P=0.511). Figure 2 displays CHD event rates accord-
ing to the number of MS criteria and the presence of
abdominal obesity in participants with either high or low CRP
levels.
Discussion
The results of the present study indicated that metabolically
healthy obese persons with low CRP levels had a trend toward
Table 2. Hazard Ratios of Coronary Heart Disease Depending on Metabolic Phenotype or the Presence of Abdominal Obesity
Stratiﬁed by C-Reactive Protein Levels
CRP, mg/L n (%) Model 1 P Value Model 2 P Value
Metabolically healthy <2 2936 (40) 0.53 (0.43–0.65) <0.001 0.60 (0.48–0.73) <0.001
≥2 1262 (17) 0.80 (0.64–1.01) 0.056 0.85 (0.68–1.01) 0.162
Metabolically unhealthy <2 1540 (21) 1 (ref) — 1 (ref) —
≥2 1541 (21) 1.37 (1.16–1.63) <0.001 1.31 (1.10–1.56) 0.002
No abdominal obesity <2 3730 (51) 0.73 (0.58–0.92) 0.008 0.75 (0.59–0.94) 0.013
≥2 1697 (23) 1.10 (0.87–1.39) 0.420 1.03 (0.81–1.30) 0.811
Abdominal obesity <2 746 (10) 1 (ref) — 1 (ref) —
≥2 1106 (15) 1.45 (1.14–1.85) 0.002 1.38 (1.08–1.75) 0.010
Metabolically healthy without
abdominal obesity
<2 2610 (36) 0.87 (0.57–1.33) 0.524 0.91 (0.60–1.39) 0.674
≥2 925 (13) 1.24 (0.80–1.94) 0.336 1.22 (0.78–1.90) 0.387
Metabolically healthy
abdominally obese
<2 326 (5) 1 (ref) — 1 (ref) —
≥2 337 (5) 1.60 (0.98–2.63) 0.063 1.59 (0.97–2.62) 0.066
Metabolically unhealthy
abdominally obese
<2 420 (6) 1.97 (1.26–3.09) 0.003 1.88 (1.20–2.94) 0.006
≥2 769 (11) 2.53 (1.67–3.83) <0.001 2.29 (1.51–3.47) <0.001
Data presented as hazard ratios and corresponding 95% CIs. Model 1 is age and sex corrected. Model 2 is corrected for age, sex, smoking, the use of lipid-lowering medication at baseline,
and low-density lipoprotein cholesterol. CRP indicates C-reactive protein.
Figure 2. CHD event rates according to the number of MS criteria and the presence of abdominal obesity
and the presence or absence of an elevated CRP level. A chi-square test was used to test for differences
between event rates between and within the speciﬁed groups. To compare differences between the groups
with no abdominal obesity and with abdominal obesity, all patients of each MS group were included in the
analyses. *P<0.05; ***P<0.01. CHD indicates coronary heart disease; CRP, C-reactive protein; MS,
metabolic syndrome; ns, not signiﬁcant.
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lower risk than metabolically healthy obese persons with
elevated levels of CRP. More important, we observed that
metabolically healthy obese persons with low CRP levels had
a CHD risk similar to that of healthy nonobese persons. These
data suggest that among metabolically healthy obese per-
sons, low CRP levels are associated with low CHD risk.
Long-Term Risk for CHD
The positive association between CRP levels and the MS and
between the MS and CHD have been studied extensively.
Previous studies suggest that those with the MS or with
elevated levels of CRP have an increased risk of CHD9,21;
however, 2 large recently published meta-analyses assessing
the associations of CRP concentration with risk of vascular
outcomes did not include the MS in their subgroup analyses.2,3
Our data indicate that metabolically unhealthy persons with
elevated CRP levels have a signiﬁcantly higher risk of future
CHD compared with metabolically unhealthy persons with CRP
levels <2 mg/dL. Ridker et al previously reported an age-
adjusted HR of 2.3 (95% CI 1.6–3.3) for women with the MS if
CRP levels <3 mg/L were present in contrast to the HR of 4.0
(95% CI 3.0–5.4) if CRP levels >3 mg/L were present.9 Rutter
et al similarly observed that CRP independently predicted CHD
above the presence of the MS in the Framingham prospective
cohort study.12 We found similar associations for abdominally
obese participants with elevated CRP levels showing an
increased risk for CHD compared with abdominally obese
participants with low CRP levels. Previous studies linking CRP
levels to CHD were performed largely in populations with a
lower prevalence of obesity than that of the current US
population.22–32 In the 2 largest published studies of CRP and
CHD disease,25,27 the mean body mass index (in kg/m2) of
participants ranged from 25 to 26, lower than the recently
reported mean of 28.7 in US adults,33 indicating the clinical
need for data regarding CRP in obese populations. The Strong
Heart Study examined the relationship between CRP levels and
CHD in an obese population with a mean body mass index
>30.34 After multivariable adjustment for traditional risk
factors, no signiﬁcant association was observed between
elevated CRP levels (>3 mg/L) and CHD events; however,
subgroup analyses examining these relationships in obese and
nonobese participants were not performed.32 Similarly, Gupta
et al reported that the association between CRP and
atherosclerosis is diminished in obese persons aged 30 to
65 years.35 The role of interleukin 6 was recently corroborated
by 3 mendelian-based association studies.36–38 Single-nucleo-
tide polymorphisms associated with decreased interleukin 6
signaling were found to correlate with lower values of acute-
phase reactants, such as CRP and ﬁbrinogen, with a
concomitant proportional reduction in cardiovascular risk.
This lower predictive accuracy of CRP in obese participants
may be affected by the close correlation between CRP and
adiposity. Interleukin 6 is the principle cytokine that stimulates
CRP release from the liver, and up to one-third of circulating
interleukin 6 is released from adipose tissue.39,40 Despite
these data suggesting a weakened association in obese versus
nonobese persons, our data showed that obese participants
with elevated levels of CRP have a higher risk of future CHD
than obese participants with CRP levels <2 mg/dL, suggesting
that CRP adds prognostic information for the obese popula-
tion, although the presence or absence of cardiometabolic risk
factors may inﬂuence the predictive value of CRP in abdom-
inally obese persons (Figure 2).
This study focused primarily on CRP and the risk of future
cardiovascular events among participants recently character-
ized by Primeau et al: metabolically healthy obese persons.
Despite having excessive body fat, these participants displayed
a favorable metabolic proﬁle characterized by high levels of
insulin sensitivity; no hypertension; and a favorable lipid,
inﬂammation, hormonal, liver enzyme, and immune proﬁle.15
Previous prospective studies provided mixed ﬁndings with
regard to the prognosis of future CHD events in the metabol-
ically healthy obese population. Three prospective studies
observed that metabolically healthy obese persons have a risk
of cardiovascular disease, mortality, and all-cause mortality
similar to that of metabolically healthy nonobese per-
sons.18,41,42 In contrast, 2 other studies suggested that,
compared with metabolically healthy nonobese persons,
metabolically healthy obese persons have a higher risk of
cardiovascular mortality and all-cause mortality.16,17 More
recently, Ortega et al showed that when accounting for ﬁtness,
cardiovascular risk was lower for metabolically healthy obese
persons compared with metabolically unhealthy obese per-
sons.19 This study suggested that metabolically healthy obese
persons might have decreased cardiovascular risk compared
with their metabolically unhealthy peers because the metabol-
ically healthy group is usually more physically ﬁt. Our study
showed that metabolically healthy obese participants with low
CRP levels had a risk of future CHD similar to that of
metabolically healthy nonobese participants as well as that of
metabolically healthy nonobese participants with elevated
CRP. These data suggest that CRP could help identify those
metabolically healthy obese persons who are at low CHD risk.
Limitations and Strengths
When interpreting the results of our study, several aspects
need to be taken into account. An important strength of this
study is the relatively large number of CHD events occurring
during follow-up (n=825). CRP levels and HRs for CHD were
similar to those observed in previous publications.3 The
prevalence of metabolic risk criteria was in agreement with
other large observational cohort studies, whereas the
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prevalence of the metabolically healthy but obese phenotype
was somewhat higher in our population compared with
previous studies,19 probably because we deﬁned abdominal
obesity by waist circumference, whereas other studies used
other measures to determine obesity (eg, body mass index).12
It must be noted that in view of the subgroups used in our
analyses, differences in our population did not always reach
our predeﬁned signiﬁcance level. This study was not designed
and powered for the current analyses; therefore, the results
should be considered as hypothesis generating and in need of
conﬁrmation in larger populations. In this prospective cohort
study, changes in lipid-lowering therapy and diet were not
recorded during follow-up. Statins and diet can decrease
systemic CRP levels. The use of such medication or changes
in diet could have altered CRP levels and the inherent
cardiovascular risk.43,44
Conclusions
We conﬁrmed a strong association between elevated CRP
levels and an increased risk of CHD in abdominally obese or
metabolically unhealthy persons. Importantly, our data indi-
cated that among metabolically healthy obese persons, low
CRP levels appeared to be associated with CHD risk
comparable to that of healthy nonobese persons.
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